epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2021-20-3-30-36epidemiology-1286Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESРаспространенность и тяжесть клинического течения новой коронавирусной инфекции среди ВИЧ-инфицированных в сравнении с общей популяциейPrevalence and Severity of New coronavirus Disease` Clinical Course among HIV-infected People in Comparison with General Populationhttps://orcid.org/0000-0002-2729-2248СергевнинВ. И.SergevninV. I.

Виктор Иванович Сергевнин – д. м. н., профессор кафедры эпидемиологии и  гигиены 

614990, г. Пермь, ул. Петропавловская, 26

Viktor I. Sergevnin – Dr. Sci. (Med.), professor of the department of Epidemiology and Hygiene

26, Petropavlovskaya str., Perm, 614990

viktor-sergevnin@mail.ruhttps://orcid.org/0000-0003-0134-1686СармометовЕ. В.SarmometovE. V.

Евгений Валерьевич Сармометов – к. м. н., главный врач 

614088, г. Пермь, ул. Свиязева, д. 21.

Evgeny V. Sarmometov – Cand. Sci. (Med.), Chief Physician

21, Sviyazeva st., Perm, 614088

sarmometov67@mail.ruРожковаМ. В.RozhkovaM. V.

Марина Владимировна Рожкова – врач-эпидемиолог

614088, г. Пермь, ул. Свиязева, д. 21.

Marina V. Rozhkova  – epidemiologist, State Healthcare Institution

21, Sviyazeva st., Perm, 614088

rozhkovamary@yandex.ruФГБОУ ВПО «Пермский государственный медицинский университет имени академика Е.А. Вагнера» Министерства здравоохранения РФРоссияPerm State Medical University named after аcademician E. A. WagnerRussian FederationГКУЗ ПК «Пермский краевой центр по борьбе и профилактике со СПИД и инфекционными заболеваниями»РоссияPerm Regional Center for Prevention and Control of AIDS and Infectious DiseasesRussian Federation2021190720212033036Copyright © Сергевнин В.И., Сармометов Е.В., Рожкова М.В., 20212021Сергевнин В.И., Сармометов Е.В., Рожкова М.В.Sergevnin V.I., Sarmometov E.V., Rozhkova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1286Актуальность

Актуальность. Вопрос о том, являются ли ВИЧ-инфицированные группой риска заболеваемости и тяжелого течения COVID-19, остается открытым.

Цель работы – определить распространенность и тяжесть клинического течения COVID-19 у ВИЧ-инфицированных в сравнении с общей популяцией.

Материалы и методы

Материалы и методы. Изучены информационные ресурсы учета COVID-19 у ВИЧ-инфицированных и ВИЧ-негативных жителей Пермского края за 2020 г.

Результаты

Результаты. Распространенность COVID-19 среди ВИЧ-инфицированных ниже, чем среди ВИЧ-негативных людей. Существенных различий в тяжести клинического течения COVID-19 у ВИЧ-инфицированных и ВИЧ-негативных не выявлено. Не обнаружено статистически значимой зависимости тяжести клинического течения COVID-19 у ВИЧ-инфицированных от количества CD4 + T-клеток и степени вирусной нагрузки.

Заключение

Заключение. ВИЧ-инфицированные не являются группой риска заболеваемости и тяжелого течения COVID-19.

Relevance

Relevance. The question about HIV-infected people as a risk group of morbidity and severe course of COVID-19 is still open.

Aim of our scientific work is to determine the prevalence and severity of COVID-19` clinical course in HIV-infected people in comparison with the general population.

Materials and methods

Materials and methods. The information resources of COVID-19 registration in HIV-infected and HIV-negative people in Perm Region were studied for 2020.

Results

Results. The prevalence of COVID-19 among HIV-infected people is lower than among HIV-negative people. There were no significant differences in the severity of COVID-19 clinical course in HIV-infected and HIV-negative people. There was no statistically significant dependence of the severity of COVID-19 clinical course in HIV-infected patients on the number of CD4 + T cells and the degree of viral load.

Conclusion

Conclusion. HIV-infected people are not a risk group of morbidity and severe course of COVID-19.

COVID-19ВИЧ-инфицированныезаболеваемостьтяжесть теченияпоказатели иммунодефицита и вирусной нагрузкиCOVID-19HIV-infectedmorbidityseverityindicators of immunodeficiency and viral loadReferencesЛадная Н. Н., Козырина Н. В., Бабихина К. А. и др. Результаты исследования «Изучение распространенности коронавирусной инфекции COVID-19 среди инфицированных ВИЧ пациентов в России и влияния эпидемии коронавирусной инфекции COVID-19 на оказание медицинской помощи при ВИЧ-инфекции». М. 2020.Ladnaya N. N., Kozyrina N. V., Babikhina K. A. et al. Results of the study «Study of the prevalence of coronavirus infection COVID-19 among HIV-infected patients in Russia and the impact of the epidemic of coronavirus infection COVID-19 on the provision of medical care for HIV infection.» M. 2020. (In Russ.).Mirzaei H, McFarland W, Karamouzian M, Hamid Sharifi H. COVID-19 Among People Living with HIV: A Systematic Review. // AIDS Behav. 2020; 1–8. doi: 10.1007/s10461-020-02983-2.Mirzaei H, McFarland W, Karamouzian M, Hamid Sharifi H. COVID-19 Among People Living with HIV: A Systematic Review. // AIDS Behav. 2020; 1–8. doi: 10.1007/s10461-020-02983-2.Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Prevalence of HIV in patients hospitalized for COVID-19 and associated mortality outcomes: a systematic review and metaanalysis. // Presented at: IDWeek 2020; October 21-25, 2020. Poster 393. doi: 10.1101/2020.07.03.20143628.Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Prevalence of HIV in patients hospitalized for COVID-19 and associated mortality outcomes: a systematic review and metaanalysis. Presented at: IDWeek 2020; October 21-25, 2020. Poster 393. doi: 10.1101/2020.07.03.20143628.Hsi-en Ho, Michael J Peluso, Colton Margus, et al. Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. The Journal of Infectious Diseases, jiaa380.Published: 30 June 2020. doi: 10.1093/infdis/jiaa380.Hsi-en Ho, Michael J Peluso, Colton Margus, et al. Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. The Journal of Infectious Diseases, jiaa380. Published: 30 June 2020. doi: 10.1093/infdis/jiaa380.Inciartea A, Gonzalez-Cordona A, Rojasa J, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. // AIDS. 2020;34(12):1775–1780. doi: 10.1097/QAD.0000000000002643.Inciartea A, Gonzalez-Cordona A, Rojasa J, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. // AIDS 2020;34(12):1775–1780. doi: 10.1097/QAD.0000000000002643.Vizcarra P, Pérez-Elías M, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. // Lancet HIV. 2020;7(8):554–564. doi: 10.1016/S2352-3018(20)30164.Vizcarra P, Pérez-Elías M, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. // Lancet HIV. 2020;7(8):554–564. doi: 10.1016/S2352-3018(20)30164Härter G, Spinner C, Roider J, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. // Infection. 2020;48(5):681–686. doi: 10.1007/s15010-020-01438-z.Härter G, Spinner C, Roider J, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. // Infection. 2020;48(5):681–686. doi: 10.1007/s15010-020-01438-z.Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. // Life Sci. 2020; Jul 15;253:117592. doi: 10.1016/j.lfs.2020.117592.AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. // Life Sci. 2020; Jul 15;253:117592. doi: 10.1016/j.lfs.2020.117592.NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. Available at: NIAIDNews@ niaid.nih.gov (Last accessed April 29, 2020).NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. Available at: NIAIDNews@ niaid.nih.gov (Last accessed April 29, 2020).Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. // Biosci Trends. 2020;14:64–68. doi: 10.5582/bst.2020.01030.Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. // Biosci Trends. 2020;14:64–68. doi: 10.5582/bst.2020.01030.Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. // J Hosp Infect. 2019;101:42–46. doi: 10.1016/j.jhin.2018.09.005.Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. // J Hosp Infect. 2019;101:42–46. doi: 10.1016/j.jhin.2018.09.005.Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. // N Eng J Med 2020; 382:1787–1799. doi:10.1056/HEJMoa2001282.Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. // N Eng J Med 2020; 382:1787–1799. doi:10.1056/HEJMoa2001282.

The authors declare that there are no conflicts of interest present.